Top Equity 2023 CAEN 21 – Fabricarea produselor farmaceutice de bază și a preparatelor farmaceutice — BizRadar
📚Work from home or in your free time.Create books with puzzle games, journals, or planners
using the PublishKAT.com platform, publish the e-file on Amazon KDP for free. Every time someone orders your book, it gets printed, delivered, and you earn the author's commission.
§ Official ranking · 2023 edition · 136 companies analyzed
Top Equity CAEN 21 – Fabricarea produselor farmaceutice de bază și a preparatelor farmaceutice, 2023
ValueEquity
CAENCAEN 21 – Fabricarea produselor farmaceutice de bază și a preparatelor farmaceutice
BizRadar rankings are deterministic — the same source data always produces the same ranking. We do not use proprietary weighting or estimates.
Eligible companies have their registered office in the respective city/county as of December 31st of the analyzed year, with financial statements filed and accepted by ANAF.
1
Primary source: ANAF
Values taken from annual financial statements filed with ANAF.
2
HQ validation: ONRC
Registered office validated as of Dec 31 via ONRC. Intra-annual changes are flagged.
3
Legal status filtering
Excluded: insolvency, liquidation, dissolution in progress, deregistration. Temporarily suspended included.
4
Currency conversion
EUR values are converted at the BNR average exchange rate for the reported fiscal year.
5
Automatic recalculation
Rankings are recalculated on each regeneration; source data corrections propagate retroactively.